Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GRN | P28799 | 1/20 | 0.32 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19700919 | 0.82 | ESR1 (0.34) | HPGDHSD17B10GRNSORT1ESR1 | |
| SCHEMBL16502348 | 0.79 | PGK1 (0.37) | HPGDTSHRHSD17B10CA1CA2 | |
| SCHEMBL18367847 | 0.76 | MAPK14 (0.32) | MAPK14 | |
| SCHEMBL7974985 | 0.74 | ALOX15 (0.39) | HPGDTSHRHSD17B10ESR1PGK1 | |
| SCHEMBL2076822 | 0.74 | HTT (0.36) | HPGDTSHRHSD17B10GRNSORT1 | |
| SCHEMBL12867277 | 0.71 | LNPEP (0.36) | — | |
| SCHEMBL3645230 | 0.71 | KDM4E (0.30) | HPGD | |
| SCHEMBL21325077 | 0.70 | ESR1 (0.33) | GRNSORT1ESR1 | |
| SCHEMBL24553502 | 0.67 | NNMT (0.41) | HPGDTSHRHSD17B10 | |
| SCHEMBL30826984 | 0.67 | ESR1 (0.49) | HPGDTSHRHSD17B10ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046160-A1 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases | PFIZER, INC. | 2011-02-24 | — | — | US | disclosed |
| US-20110046160-A1 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases | PFIZER, INC. | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046160-A1 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases | SNCA, PARK7, HTT | HPGD 516/4885TSHR 2618/4885HSD17B10 2736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.